Neuphoria Therapeutics Inc (NEUP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neuphoria Therapeutics Inc stock (NEUP) is currently trading at $4.37. Neuphoria Therapeutics Inc PS ratio (Price-to-Sales) is 1.66. Analyst consensus price target for NEUP is $9.77. WallStSmart rates NEUP as Sell.
- NEUP PE ratio analysis and historical PE chart
- NEUP PS ratio (Price-to-Sales) history and trend
- NEUP intrinsic value — DCF, Graham Number, EPV models
- NEUP stock price prediction 2025 2026 2027 2028 2029 2030
- NEUP fair value vs current price
- NEUP insider transactions and insider buying
- Is NEUP undervalued or overvalued?
- Neuphoria Therapeutics Inc financial analysis — revenue, earnings, cash flow
- NEUP Piotroski F-Score and Altman Z-Score
- NEUP analyst price target and Smart Rating
Neuphoria Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Neuphoria Therapeutics Inc (NEUP) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Neuphoria Therapeutics Inc (NEUP) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Paying $1.66 for every $1 of annual revenue
50.31% held by institutions, strong professional interest
Supporting Valuation Data
Neuphoria Therapeutics Inc (NEUP) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Neuphoria Therapeutics Inc (NEUP) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 8.7/10) while 4 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (1.66), Price/Book (0.84) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Profitability pressure is visible in Return on Equity at -26.10%, Operating Margin at -12.40%, Profit Margin at -37.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NEUP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NEUP's Price-to-Sales ratio of 1.66x sits near its historical average of 1.6x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 3% below its historical high of 1.71x set in Mar 2026, and 11% above its historical low of 1.49x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~1.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neuphoria Therapeutics Inc (NEUP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Neuphoria Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. The company is currently unprofitable, posting a -37.8% profit margin.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 14M in cash.
The company is unprofitable with a -37.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Neuphoria Therapeutics Inc.
Bottom Line
Neuphoria Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 12:56:17 PM
About Neuphoria Therapeutics Inc(NEUP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company devoted to developing pioneering therapies for mental health disorders, utilizing psychedelic compounds and advanced drug delivery technologies. With a strong focus on translating cutting-edge research into effective treatments for significant unmet needs in the mental health sector, Neuphoria is establishing itself as a leader in this rapidly evolving industry. The company boasts a robust pipeline of preclinical candidates, making it an attractive investment opportunity for institutional investors seeking to capitalize on the next wave of biotech innovations. Neuphoria's commitment to delivering transformative therapeutic solutions positions it as a key player in redefining the future of mental health care.